NCT05838079

Brief Summary

Copenhagen Baby Heart Study - Impact (CBHS-I) is an extension to Copenhagen Baby Heart (CBH) which included over 25.000 new-borns in the Copenhagen area between 2016-2018. Based on clinical and subclinical deviations in the examinations in CBH, subgroups of participants will be invited to clinical examinations (echocardiography and electrocardiogram) in early childhood. There will also be a new, targeted inclusion based on certain exposures during pregnancy. The main objectives are to assess the prevalence of congenital and inherited heart disease and, and the development of these during early childhood; examining the association between pre- and postnatal exposure, disease, lifestyle, environmental and genetic factors; continue to establish reference values for echocardiography in Danish neonates and children.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35,000

participants targeted

Target at P75+ for all trials

Timeline
38mo left

Started Nov 2018

Longer than P75 for all trials

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress70%
Nov 2018Jul 2029

Study Start

First participant enrolled

November 1, 2018

Completed
4.5 years until next milestone

First Submitted

Initial submission to the registry

April 20, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

May 1, 2023

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2029

Last Updated

May 1, 2023

Status Verified

April 1, 2023

Enrollment Period

10.7 years

First QC Date

April 20, 2023

Last Update Submit

April 20, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prevalence of congenital heart disease

    10 years

Study Arms (3)

New-borns (CBHS-I)

New-borns, within the first 30 days of birth.

Other: Clinical examination

Children (CBH and CBHS-I)

Children, 3-13 years of age. The children from the original inclusion in CBH, and those included in CBHS-I.

Other: Clinical examination

Family members

Children and adults, age 1-99 years of age. Some subprojects will invite the family members of the participating child for family examinations.

Other: Clinical examination

Interventions

Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation

Children (CBH and CBHS-I)Family membersNew-borns (CBHS-I)

Eligibility Criteria

Age1 Day - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Participants from CBH and in some cases their family members. New-borns of mothers with pre-existing or gestational diabetes, included during CBHS-I.

You may qualify if:

  • Participant in CBH or
  • Family member of a participant in CBH or
  • Born to mothers with pre-existing or gestational diabetes at either Rigshospitalet, Hvidovre Hospital, or Herlev Hospital during the period July 2020 through December 2023.

You may not qualify if:

  • Faliure of providing concent (parents)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Rigshospitalet Copenhagen University Hospital.

Copenhagen Ø, 2100, Denmark

RECRUITING

Herlev and Gentofte Hospital

Herlev, 2730, Denmark

RECRUITING

Hvidovre Hospital

Hvidovre, 2650, Denmark

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Venous and/or umbilical cord blood sample for DNA extraction and analysis of biomarkers

MeSH Terms

Conditions

Heart Defects, Congenital

Interventions

Restraint, Physical

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Behavior ControlTherapeuticsImmobilizationInvestigative Techniques

Study Officials

  • Henning Bundgaard, MD, DMSc

    Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen University Hospital, Denmark

    PRINCIPAL INVESTIGATOR
  • Kasper Iversen, MD, DMSc

    Department of Cardiology, Herlev Hospital, Denmark.

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Henning Bundgaard, MD, DMSc

CONTACT

Kasper Iversen, MD, DMSc

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 20, 2023

First Posted

May 1, 2023

Study Start

November 1, 2018

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

July 1, 2029

Last Updated

May 1, 2023

Record last verified: 2023-04

Locations